Rheumatologist Survey to Assess the Effectiveness of the Risk Minimisation Measures (RMM) for Olumiant® (baricitinib) a JAK1/2 inhibitor (I4V-MC-B010)

01/02/2019
02/07/2024
EU PAS number:
EUPAS25154
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

B010 PASS Version 1.0 Nov2018_Redacted

English (5.41 MB - PDF) View document
Study results
Study results

Lilly EU baricitinib HCP PASS v1.0 (1)_Redacted

English (6.95 MB - PDF) View document
Study report
Other information